Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). clinical trials

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

This study looks at new ways to treat an aggressive type of breast cancer called triple-negative breast cancer (TNBC). It compares Olaparib alone to Olaparib combined with other drugs, aiming to find safer, more effective treatments, especially for those with specific genetic changes.